18 results about "Atopic dermatitis (eczema)" patented technology

The present invention relates generally to maqui berry for use in the treatment or prevention of skin diseases, wherein maqui berry may be the primary natural active ingredient. Particular embodiments as disclosed herein find application in, inter alia, the prophylaxis and the treatment of skin diseases, in particular, dermatitis, atopic dermatitis (neurodermatitis), dermatitis solaris, eczema, hand eczema, lichen planus, lupus erythematosus, psoriasis, urticaria, itching, scabies, age spot, freckles and dry / atopic skin of humans. In particular, the present invention relates to the use of maqui berry extract in the manufacture of a medicament or dietary supplement for use in treating or preventing said skin diseases or defects.

The invention relates to the technical field of skin medicines, in particular to a pharmaceutical composition for preventing or treating inflammatory skin diseases and application. The invention discloses a pharmaceutical composition for preventing or treating inflammatory skin diseases and application. The composition comprises active ingredients of astacin and derivatives thereof, p-toluene sulfonamide and derivatives thereof, and pharmaceutically or cosmetically acceptable excipients. Through the synergistic effect of the two active components, the composition can effectively inhibit skin inflammatory response, relieve pruritus and erythema and promote skin barrier repair and wound healing. The composition can be prepared into multiple external dosage forms such as cream, gel and spray, is suitable for preventing or treating multiple inflammatory skin diseases such as atopic dermatitis, eczema and psoriasis, and can also be used for repairing and nursing skin wounds. The external formula provided by the invention has both curative effect and safety, and provides a new choice for the treatment of inflammatory dermatosis.

The application discloses application of a human lactoferricin peptide in anti-inflammatory soothing and skin barrier repair. The application relates to the field of biotechnology, and provides application of a polypeptide or a biological material related to the polypeptide in preparation of a product with anti-inflammatory soothing and / or skin barrier repair functions; the polypeptide is a human lactoferricin peptide derived from a filtrate of a yeast fermentation lysate product, and an amino acid sequence of the polypeptide is shown as SEQ ID NO:1. The polypeptide has intervention potential on inflammation related to dermatitis and eczema, especially on atopic dermatitis. The polypeptide can be applied to the fields of medicines and cosmetics.

The present disclosure is related to a topical formulation comprising clascoterone in a mixture of aqueous and oily gel phases. The present disclosure further relates to a method of treating or preventing skin conditions such acne vulgaris, acne conglobata, acne fulminans, androgenetic alopecia, hidradenitis suppurativa (also known as acne inversa), hirsutism, cancer-therapy-induced rash, eczema, rosacea, atopic dermatitis, psoriasis, inverse psoriasis, seborrheic dermatitis, acanthosis nigricans, wound, and female pattern hair loss, comprising topically administering to a subject in need thereof an effective amount of the formulation.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation in the skin, e.g., atopic dermatitis, eczema other than atopic dermatitis, hidradenitis suppurativa, vitiligo, alopecia areata, scleroderma (including systemic sclerosis), dermatomyositis, epidermolysis bullosa, mastocytosis, keloids, acne, rosacea, or bullous pemphigoid, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody (Afimkibart).

The invention discloses an anemoside B4 derivative as well as a preparation method and application thereof, a compound anemoside B4 (abbreviated as B4 or AB4) is taken as a raw material, and the derivative is prepared by respectively carrying out nucleophilic substitution, electrophilic addition, esterification reaction or amidation and other reactions on C-19 exocyclic double bonds or C-28 carboxyl. The compound is used as an active component to prepare medicines with anti-inflammatory and immunoregulation effects. The invention discloses the effect of the B4 derivative on treating inflammatory diseases such as inflammatory bowel disease, atopic dermatitis, eczema and psoriasis for the first time, and the drug effect of the B4 derivative is superior to that of B4 or clinically common drugs. In addition, the invention also discloses that most B4 derivatives do not show obvious cytotoxicity to macrophages for the first time, can reduce the P-I kappa Ba protein level in LPS and ATP induced macrophage NF-kappa B signaling pathways, inhibit the activation of NLRP3 signaling pathways and obviously reduce the Pro-IL-1beta level (p is less than 0.05), namely inhibit the activation of inflammasome pathways, and the effect is superior to that of B4; the results show that the B4 derivative disclosed by the invention has better anti-inflammatory activity.

The present invention relates to interleukin 18 (IL-18) antibody therapies, low dose formulations of anti-IL-18 neutralizing antibodies, and the use of such formulations for the treatment of IL-18 related diseases by subcutaneous administration. The invention further relates to the use of said anti-IL-18 neutralizing antibody low-dose formulations in the treatment of e.g., adult pathogenic Stetill Disease (AOSD) or systemic pathogenic juvenile idiopathic arthritis (SoJIA, SoJIA, SoJIB, SoJIA, SoJIB, SoJIA, SoJIA, SoJIA, SoJIA, the present invention relates to the use thereof in Still disease such as Still disease (e.g., juvenile Still disease), atopic eczema or atopic dermatitis (AD), inflammatory bowel disease such as ulcerative colitis (UC) and Crohn's disease (CD), and eosinophilic esophagitis (EoE).

The recurrence rate of atopic dermatitis is extremely high, the recurrence rate of moderate and severe atopic dermatitis is 37-53% every year, and the living quality of patients is greatly affected. The invention provides the traditional Chinese medicine composition for treating atopic dermatitis by taking'spleen strengthening, kidney nourishing, yin nourishing and dryness moistening 'as a core treatment rule, and the traditional Chinese medicine composition can relieve skin itch, promote skin lesion fading and reduce the recurrence rate. The traditional Chinese medicine composition accords with the idea of'prevention of disease 'of traditional Chinese medicine, has important value in chronic disease management, and has good effectiveness and safety through clinical verification. Meanwhile, the application of the invention can reduce the medical expenditure of disease recurrence, and has good economic value. At present, no medicine for controlling atopic dermatitis or eczema relapse exists in the market, and the research of the project proves that the traditional Chinese medicine composition has a remarkable curative effect on prevention of atopic dermatitis relapse.

This disclosure relates to compounds of formula (I-1) or (I-2): This relates to TIFF2026513962000575.tif74102. The compounds of this disclosure can inhibit the activity of tyrosine kinase 2 (TYK2), for example, in inflammation, autoimmune diseases, neuroinflammation, arthritis, rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, lupus nephritis, arthritis, osteoarthritis, gouty arthritis, pain, fever, pulmonary sarcoidosis, silicosis, cardiovascular disease, atherosclerosis, myocardial infarction, thrombosis, congestive heart failure and cardiac reperfusion injury, cardiomyopathy, stroke, ischemia, reperfusion injury, cerebral edema, head trauma, neurodegeneration, liver disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, nephritis, retina It is useful in treating diseases or disorders such as inflammation, retinopathy, macular degeneration, glaucoma, diabetes (type 1 and type 2), diabetic neuropathy, viral and bacterial infections, myalgia, endotoxin shock, toxic shock syndrome, autoimmune diseases, osteoporosis, multiple sclerosis, endometriosis, menstrual pain, vaginitis, candidiasis, cancer, fibrosis, obesity, muscular dystrophy, polymyositis, dermatomyositis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, vitiligo, alopecia, Alzheimer's disease, skin flushing, eczema, psoriasis, atopic dermatitis, and sunburn. This disclosure further provides a method for preparing the compound.

The present invention relates to a compound of formula (I) wherein R1 and R2 are as defined herein, a pharmaceutical composition comprising such compound for treatment of a PGD2-mediated disorder including, to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like.

A method for manufacturing medicinal fabric that provides enhanced dermatological comfort for the user / patient, especially those with sensitive skin conditions (e.g., acne, contact dermatitis, atopic dermatitis, eczema, psoriasis, rosacea, urticaria, etcetera) including the steps of: (1) selecting a cotton fiber, wherein the cotton fiber is long staple cotton and 100 percent organic; (2) processing the cotton fiber as greige cotton; (3) optionally verifying that the cotton fiber is organic per Global Organic Textile Standards or comparable standards; (4) fermenting or otherwise naturally preparing an herb or plant into a medicinally potent agent / substance and hypoallergenic dyeing agent; (5) using a skin-friendly binding technique, such as binderless dyeing the cotton fiber with the agent / substance via ultrasonic energy or using a technique that similarly uses no irritative chemical binders; (6) selecting a suitable weave type for the specific use / case to reduce mechanical irritation to the user / patient; (7) optionally verifying that the woven cotton fiber has not been contaminated during the manufacturing process through toxicological verification methods; and (8) optionally verifying that the woven cotton fiber passes the standardized dermatological Human Repeat Insult Patch Test.

The present application belongs to the technical field of biological medicine, and particularly relates to a composition for treating atopic dermatitis and application thereof. The mass ratio of each component of the composition is: notoginseng extract: artemether: wujin glycoside: oleanolic acid = (2-4):(2-4):(1-2):(1-2). The composition has the effects of anti-inflammation and anti-itching, and can treat atopic dermatitis, eczema and other diseases. The active ingredients of the composition are all of plant origin, have good safety and the treatment effect on atopic dermatitis, and have a low dosage. The components can achieve a synergistic effect, and show excellent effects. The composition can be applied to functional skin care products (cream, emulsion, essence) and external drugs (ointment).

The invention discloses an application of betulinic acid 28-O-beta-D-glucoside (BA-6 for short) in preparation of a medicine for preventing and treating skin inflammation. The problems that an existing medicine for treating dermatitis is limited in curative effect, slow in effect taking, multiple in side effect, high in long-term use risk, large in individual difference, high in treatment cost, likely to cause immunoreaction and the like are solved. The invention discloses application of BA-6 in prevention and treatment of atopic dermatitis, contact dermatitis, eczema, rash, psoriasis, lupus erythematosus, papule squamous skin disease, pityriasis rosea, seborrheic dermatitis, pemphigus, celestial abscess, acne, tinea corporis, impetigo, SAPHO syndrome, hidradenitis suppurativa, dermatitis caused by drugs, lichen planus, pityriasis rubra pilaris, vitiligo, prurigo nodularis, dermatitis caused by drugs, and the like for the first time. The traditional Chinese medicine composition can be used for treating skin diseases, systemic sclerosis, hidradenitis suppurativa, granulomatous skin diseases, vitiligo, dermatomyositis, chronic skin itch and alopecia areata, and has the technical progress of obviously improving skin erythema, papule, edema, scale, moss and ulceration symptoms.

The invention discloses a traditional Chinese medicine lotion for treating intractable skin diseases. The traditional Chinese medicine lotion is prepared from the following raw material medicines: agastache rugosus, rhizoma acori graminei, radix clematidis, mint, cicada slough, nidus vespae, radix angelicae, rhizoma cyperi, fructus cnidii, fructus kochiae, rhizoma dioscoreae, radix cynanchi paniculati, cortex dictamni, tribulus terrestris, silkworm larva, snake slough, gallnut, radix rehmanniae, cortex moutan, cortex lycii radicis, clove, ligusticum wallichii and liquorice. According to the invention, the traditional treatment mode of pressing the pathogenic factors in the body is changed into the mode of discharging the pathogenic factors in the body out of the body, so that the current situation that the pathogenic factors are treated when the medicine is used, and the medicine is stopped and repeatedly used is fundamentally solved, the idea that the atopic dermatitis cannot be cured is broken, and the cure rate of the eczema and the dermatitis reaches 95% or above; and all the traditional Chinese medicinal materials in the prescription are conventional medicinal materials, are free of rare and expensive medicines, are low in price, are less than 10 yuan in one day, are low in treatment cost, and bring good news to a large number of economical and constraining patients.

The invention relates to the field of medicine, specifically to the field of treatment of dermatitis or eczema, even more specifically to the field of treatment of atopic dermatitis. The invention relates to a novel composition and a novel kit of parts, both comprising an anti-inflammatory compound and a compound specifically targeting a bacterial cell, preferably a gram positive bacterial cell. The invention further relates to said composition and / or kit of parts for medical use, preferably for treating an individual suffering from eczema.

The invention discloses a lactobacillus gasseri BDUP (Lactobacillus gasseri) strain and application of the lactobacillus gasseri BDUP strain in preparation of drugs for treating atopic dermatitis or eczema. The preservation number of the lactobacillus gasseri BDUP strain is CGMCC (China General Microbiological Culture Collection Center) No. 18357. Different from existing probiotics which take effect mainly by resisting histamine or regulating Th1 / Th2 balance, the invention discloses a unique nerve-immune bidirectional regulation mechanism of the BDUP strain for the first time, and the BDUP strain can significantly down-regulate expression levels of a neuropeptide P substance (Substance P), a calcitonin gene-related peptide (CGRP), a nerve growth factor (NGF) and a pruritus specific factor IL-31 in skin tissues, so that the BDUP strain can be used for treating skin pruritus. Therefore, neurogenic inflammation and a pruritus conduction pathway are effectively blocked. Animal experiments show that the BDUP strain can shorten the scratching time of eczema model mice by about 80%, the itching relieving and anti-inflammatory effects of the BDUP strain are equivalent to those of potent glucocorticoid, and the BDUP strain has no side effect. The invention provides a novel efficient biological treatment scheme for solving intractable pruritus caused by eczema.

The application belongs to the field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating skin diseases and application thereof. The traditional Chinese medicine composition takes the core principle of 'nourishing kidney and strengthening spleen, and promoting lung and removing dampness' as the core principle, provides a traditional Chinese medicine for treating skin diseases with fast effect, high safety and better curative effect, and provides an optimized scheme for treating atopic dermatitis or eczema for patients with spleen-kidney deficiency, lung depression and dampness accumulation. The kidney-nourishing and spleen-strengthening lung-promoting drink has a significant curative effect on atopic dermatitis, has a better taste, is more easily accepted by children, and has a good application prospect in the market.